Poly(ethylene glycol) (PEG) is the most widely used polymer in delivering anticancer drugs clinically. PEGylation (i.e., the covalent attachment of PEG) of peptides proteins, drugs, and bioactives is known to enhance the aqueous solubility of hydrophobic drugs, prolong circulation time, minimize nonspecific uptake, and achieve specific tumor targetability through the enhanced permeability and retention effect. Numerous PEG-based therapeutics have been developed, and several have received market approval. A vast amount of clinical experience has been gained which has helped to design PEG prodrug conjugates with improved therapeutic efficacy and reduced systemic toxicity. However, more efforts in designing PEG-based prodrug conjugates are anticipated. In light of this, the current paper highlights the synthetic advances in PEG prodrug conjugation methodologies with varied bioactive components of clinical relevance. In addition, this paper discusses FDA-approved PEGylated delivery systems, their intended clinical applications, and formulations under clinical trials.
Eur J Med Chem. 2004 Feb;39(2):123-33
[PMID:
14987821]
Curr Drug Targets. 2004 May;5(4):389-406
[PMID:
15134222]
J Control Release. 2001 Jul 6;74(1-3):225-32
[PMID:
11489498]
Int J Nanomedicine. 2006;1(3):241-54
[PMID:
17717965]
Drug Metab Dispos. 2007 Jan;35(1):9-16
[PMID:
17020954]
Lancet. 2006 Sep 9;368(9539):947-53
[PMID:
16962885]
Oncologist. 2007 Aug;12(8):991-8
[PMID:
17766659]
Adv Drug Deliv Rev. 2009 Nov 12;61(13):1177-88
[PMID:
19671438]
Int J Pharm. 2004 Jun 11;277(1-2):63-72
[PMID:
15158969]
J Biol Chem. 1977 Jun 10;252(11):3578-81
[PMID:
405385]
J Control Release. 2000 Mar 1;65(1-2):271-84
[PMID:
10699287]
Science. 1992 Jun 19;256(5064):1677-80
[PMID:
1535167]
N Engl J Med. 2000 Apr 20;342(16):1171-7
[PMID:
10770982]
Crit Rev Ther Drug Carrier Syst. 1990;6(4):315-65
[PMID:
2186872]
Adv Drug Deliv Rev. 2003 Sep 26;55(10):1303-14
[PMID:
14499709]
J Biol Chem. 1977 Jun 10;252(11):3582-6
[PMID:
16907]
Ann Oncol. 2003 Jan;14(1):29-35
[PMID:
12488289]
N Engl J Med. 2000 Dec 7;343(23):1666-72
[PMID:
11106715]
Bioconjug Chem. 2008 Apr;19(4):849-59
[PMID:
18370417]
Lancet. 2008 Jul 12;372(9633):117-26
[PMID:
18620949]
Cancer. 2003 Jul 1;98(1):94-9
[PMID:
12833461]
Arthritis Res Ther. 2006;8(1):R12
[PMID:
16356199]
Lancet. 2001 Nov 24;358(9295):1754-9
[PMID:
11734231]
Cancer. 1976 Jan;37(1):220-8
[PMID:
1061636]
Curr Opin Investig Drugs. 2008 Apr;9(4):422-9
[PMID:
18393109]
Curr Pharm Des. 2004;10(11):1235-44
[PMID:
15078138]
Nat Rev Drug Discov. 2011 Jan;10(1):17-8
[PMID:
21193861]
J Control Release. 2002 Feb 19;79(1-3):41-53
[PMID:
11853917]
J Pharm Sci. 2010 Jun;99(6):2557-75
[PMID:
20049941]
J Clin Oncol. 2005 Feb 20;23(6):1178-84
[PMID:
15718314]
Cancer Chemother Pharmacol. 2001;47(1):83-8
[PMID:
11221967]
Eur J Cancer. 2004 Jan;40(1):148-57
[PMID:
14687799]
Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12962-7
[PMID:
16123131]
Curr Opin Biotechnol. 2011 Aug;22(4):492-501
[PMID:
21676609]
Bioorg Med Chem. 2002 Sep;10(9):3023-9
[PMID:
12110325]
Am J Nephrol. 2008;28(5):732-43
[PMID:
18434712]
J Drug Target. 2007 Aug-Sep;15(7-8):457-64
[PMID:
17671892]
J Mol Endocrinol. 2002 Aug;29(1):11-4
[PMID:
12200225]
Cancer. 2002 Jul 15;95(2):389-96
[PMID:
12124839]
Arthritis Rheum. 2007 Mar;56(3):1021-8
[PMID:
17328081]
Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70
[PMID:
18398613]
Lancet. 2001 Sep 22;358(9286):958-65
[PMID:
11583749]
Drug Metab Dispos. 1986 May-Jun;14(3):349-52
[PMID:
2872037]
J Control Release. 2003 Aug 28;91(1-2):61-73
[PMID:
12932638]
Biotechnol Bioeng. 1999 Aug 20;64(4):418-25
[PMID:
10397880]
J Control Release. 2002 Feb 19;79(1-3):55-70
[PMID:
11853918]
Adv Drug Deliv Rev. 2004 Mar 3;56(4):491-509
[PMID:
14969755]
Adv Drug Deliv Rev. 2008 Jan 3;60(1):29-49
[PMID:
17884239]
Bioconjug Chem. 2001 Mar-Apr;12(2):195-202
[PMID:
11312680]
Biomaterials. 2010 May;31(15):4268-77
[PMID:
20206990]
Nat Rev Drug Discov. 2003 May;2(5):347-60
[PMID:
12750738]
Mol Cancer Ther. 2010 Nov;9(11):3052-64
[PMID:
20978165]
Nat Rev Drug Discov. 2003 Mar;2(3):214-21
[PMID:
12612647]
J Control Release. 2008 May 8;127(3):239-48
[PMID:
18346806]
Cancer. 1995 Mar 1;75(5):1176-81
[PMID:
7850718]
Blood. 1996 Sep 15;88(6):1907-29
[PMID:
8822908]
J Control Release. 2001 Jul 6;74(1-3):47-61
[PMID:
11489482]
Br J Haematol. 2000 Jun;109(3):549-54
[PMID:
10886203]
N Engl J Med. 2002 Sep 26;347(13):975-82
[PMID:
12324553]
Angew Chem Int Ed Engl. 2006 Feb 13;45(8):1198-215
[PMID:
16444775]
Clin J Am Soc Nephrol. 2006 Nov;1(6):1211-5
[PMID:
17699350]
Nat Rev Cancer. 2006 Sep;6(9):688-701
[PMID:
16900224]
Cancer. 1999 Oct 1;86(7):1203-9
[PMID:
10506705]
Trends Biotechnol. 1995 Mar;13(3):86-91
[PMID:
7766222]
J Clin Oncol. 2000 Jun;18(12):2444-58
[PMID:
10856105]
Adv Drug Deliv Rev. 2002 Jun 17;54(4):571-86
[PMID:
12052715]
Br J Haematol. 2001 Apr;113(1):115-9
[PMID:
11328290]
Expert Opin Emerg Drugs. 2009 Jun;14(2):363-80
[PMID:
19453284]
Clin Immunol. 2007 May;123(2):139-47
[PMID:
17300989]
Angew Chem Int Ed Engl. 2010 Aug 23;49(36):6288-308
[PMID:
20648499]
Adv Drug Deliv Rev. 2008 Jan 3;60(1):59-68
[PMID:
17826865]
Am J Nephrol. 2006;26(2):149-56
[PMID:
16636531]
J Org Chem. 2000 Jul 28;65(15):4601-6
[PMID:
10959865]
Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302
[PMID:
14499708]
J Pept Sci. 2001 Sep;7(9):511-8
[PMID:
11587190]
N Engl J Med. 1987 Mar 5;316(10):589-96
[PMID:
3807953]
Eur J Cancer. 1995;31A(5):766-70
[PMID:
7640051]
